FDA approves Retatrutide this year?

根据「FDA approves Retatrutide this year?」的最新预测市场数据，交易者已形成强烈共识。

目前，No 以压倒性的 88.5% 获胜概率主导市场；Yes 以 11.5% 位居第二。该市场的下注量已达 $569.8K，反映出市场的高度关注。

为了更好地评估各潜在结果的位置，可依据隐含概率与合约定价将市场划分为三个明显的交易梯队：

🥇 第一梯队：绝对领跑者

• No (88.5%)：No 目前拥有最高概率，深受订单簿青睐。看好该结果的交易者面对的「Buy Yes」合约价为 89¢，显示出市场的高度确信。

🥈 第二梯队：主要挑战者

• Yes (11.5%)：作为最可行的替代选项，Yes 保持着 11.5% 的成真概率，其「Buy Yes」份额目前成交价为 12¢。

Retatrutide is a triple agonist hormone/peptide drug developed by Eli Lilly and currently in trial to treat obesity, fatty liver disease, type-2 diabetes, knee osteoarthritis, and more.

This market will resolve to "Yes" if the U.S. Food and Drug Administration (FDA) grants a full or conditional approval for Eli Lilly’s for a drug product whose active ingredient is Eli Lilly’s retatrutide (including any brand name or identifier such as LY3437943) for any use between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No."

An approval is defined as:

For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA)

For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced

For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA)

For biosimilars: FDA approval of a 351(k) application

The following constitute qualifying approvals:

Standard approval (traditional approval based on clinical benefit), Accelerated approval (based on surrogate endpoints), Approval with Risk Evaluation and Mitigation Strategy (REMS), Approval with restricted distribution or indication limitations, except compassionate use/expanded access programs

The following do not constitute qualifying approvals:

Approvable letters that require additional actions before approval

Tentative approvals pending patent or exclusivity expiration

FDA requests for additional information or studies

Extension of Prescription Drug User Fee Amendments dates

Approval for compassionate use or expanded access programs only

Approval only for export or for use outside the United States

Emergency Use Authorization (EUA) without full approval

Complete Response Letters (CRLs) indicating the application cannot be approved in its current form

If the listed drug is approved within this market’s timeframe, the market will resolve to "Yes," regardless of potential Advisory Committee votes against approval or later withdrawal of approval.

Conditional approvals may include post-marketing requirements or commitments and still qualify.

The primary resolution source will be official information from the FDA; however, a consensus of credible reporting will also be used.

人群共识与投机成交塑造了更宏观的预测市场，而我们的量化算法提供了数据驱动的反向视角。通过分析基本面信号、底层趋势与历史分布，我们的 AI 估值模型为每个结果独立测算出一个「公允价值」概率。

将该公允价值与当前交易价值对比，可揭示出重大背离——即期望值（EV）差。正 EV 差代表统计上被低估的结果，而负 EV 差则提示市场可能存在反应过度。

顶级 AI Alpha 与错误定价套利机会

根据最新一轮数据模型测算，以下几个关键合约存在显著偏离：

• 最被高估的结果：No 当前交易价为 88.5%，但我们的 AI 测算其公允价值仅为 82.2%，形成 -6.3% 的较大负 EV 差，表明人群可能过度炒作该结果、把溢价推得过高。
• 最佳价值标的（最高 EV）：我们的模型将 Yes 识别为盘面上最具价值的机会。市场仅给予其 11.5% 的交易概率，而我们 AI 的公允价值评估为 17.8%——形成可观的 +6.3% EV 差。